ASCO_iPlannerAM2015_Tuesday
Session Title: Highlights of the Day Session III
Session Type: Highlights of the Day Session
Track: Special Sessions
Time: 7:30 AM - 9:15 AM
Location: E Hall D1
?
Chair Apar Kishor Ganti, MD - Chair ?
Breast Cancer Eric P. Winer, MD ?
Developmental Therapeutics - Immunotherapy Ian D. Davis, MBBS, PhD, FRACP, FAChPM ?
Genitourinary (Nonprostate) Cancer Peter Albers, MD ?
Gynecologic Cancer Kunle Odunsi, MD, PhD ?
Head and Neck Cancer Quynh-Thu Le, MD ?
Sarcoma Jonathan C. Trent, MD, PhD ?Tumor Biology
Mark M. Moasser, MD
Session Title: Adjuvant Treatment of Soft Tissue Sarcoma: What, When, and Why
Session Type: Education Session
Track: Sarcoma
Time: 8:00 AM - 9:15 AM
Location: S504
?Optimization of Surgical Resection for Soft Tissue Sarcoma
H. Thomas Temple, MD
ASCO Annual Meeting Express Print
Tuesday, June 2, 2015
Program data current as of Wednesday, May 13, 2015
?Is There a Role for Adjuvant Chemotherapy for Resected Soft-Tissue Sarcoma?
Paolo Giovanni Casali, MD - Chair
?What Are the Indications for Adjuvant Radiation for Resected Soft-Tissue Sarcomas?
Brian O'Sullivan, MD
?Panel Question and Answer
Session Title: Integrative Cancer Prevention: Nutrition, Supplements, and Lifestyle Session Type: Education Session
Track: Cancer Prevention, Genetics, and Epidemiology
Time: 8:00 AM - 9:15 AM
Location: S102
?Can Correct Diet and Exercise Choices Prevent Cancer?
Michelle Harvie, PhD
?Clinical Practice Guidelines on the Use of Integrative Therapies During Breast Cancer Treatment
Heather Greenlee, ND, PhD
?Lifestyle Modification and Dietary Supplements in Secondary Prevention Donald I. Abrams, MD - Chair
?Panel Question and Answer
Session Title: New Targets and Therapies for Triple-Negative Breast Cancer
Session Type: Education Session
Track: Breast Cancer
Time: 8:00 AM - 9:15 AM
Location: E450
?Illuminating the Biology of Triple-Negative Breast Cancer
Brian D. Lehmann, PhD
?Immunology and Triple-Negative Disease
Mary L. Disis, MD
?Novel Therapies for Triple-Negative Breast Cancer
Antoinette R. Tan, MD - Chair
?Panel Question and Answer
Session Title: Personalized Therapy for Multiple Myeloma in a Value-Oriented Environment Session Type: Education Session
Track: Lymphoma and Plasma Cell Disorders
Time: 8:00 AM - 9:15 AM
Location: E354b
?Smoldering Multiple Myeloma: When to Observe and When to Treat?
María-Victoria Mateos, MD, PhD
?Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?
Saad Zafar Usmani, MD - Chair
?Multiple Myeloma: How to Sequence Therapy?
Philippe Moreau, MD
?Panel Question and Answer
Session Title: Targeting Cancer Metabolism
Session Type: Education Session
Track: Tumor Biology
Time: 8:00 AM - 9:15 AM
Location: S100bc
?Lessons from IDH: Understanding Basic Metabolic Pathways and Translation to Clinical Trials W. Marston Linehan, MD - Chair
?Metabolic Reprogramming of the Immune Response in the Tumor Microenvironment Jeff Rathmell, PhD
?Identification of New Metabolic Targets from Metabolic Tracer Studies in Patients Robert Bachoo, MD, PhD
?Panel Question and Answer
Session Title: Central Nervous System Tumors
Session Type: Oral Abstract Session
Track: Central Nervous System Tumors
Time: 8:00 AM - 11:00 AM
Location: S404
?Co-chair
Manmeet Singh Ahluwalia, MD
?Co-chair
Lakshmi Nayak, MD
?Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. (Abstract 2000)
Roger Stupp
?Long-term analysis of the NOA-04 randomized phase III trial of sequential
radiochemotherapy of anaplastic glioma with PCV or temozolomide. (Abstract 2001)
Wolfgang Wick
?Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic
astrocytoma (AA). (Abstract 2002)
Susan Marina Chang
?Radiation, Chemotherapy, or More for Newly Diagnosed, High-Grade Gliomas Martin J. Van Den Bent, MD
?Panel Question and Answer
?Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study,
a prospective randomized phase II trial in patients with recurrent glioblastoma. (Abstract
2003)
Elizabeth J. Hovey
?NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM). (Abstract 2004)
Evanthia Galanis
? A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. (Abstract 2005)
Shiao-Pei S. Weathers
?Bevacizumab for Glioblastoma: Selection, Dose, and Schedule
Timothy F. Cloughesy, MD
?Panel Question and Answer
Panel Discussion
?Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033) in patients with a high risk low-grade glioma. (Abstract 2006)
Brigitta G. Baumert
?Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling. (Abstract 2007)
Michael Weller
?The landscape and clonal architecture in lower grade glioma. (Abstract 2008) Hiromichi Suzuki
?Molecular Determinants in the Management of Gliomas
Howard Alan Fine, MD
?Panel Question and Answer
Panel Discussion
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Session Type: Oral Abstract Session
Track: Developmental Therapeutics and Translational Research
Time: 8:00 AM - 11:00 AM
Location: S100a
?Co-chair
Timothy Anthony Yap, MD, PhD
?Co-chair
Emiliano Calvo, MD, PhD
? A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. (Abstract 2500)
Udai Banerji
?First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies. (Abstract 2501)
Dejan Juric
?PI3K Pathway as a Target: Early-Phase Data
Filip Janku, MD, PhD
?Panel Question and Answer
?Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). (Abstract 2503)
John A. Thompson
?Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.
(Abstract 2504)
Michael J. Guarino
? A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study. (Abstract 2505)
Efrat Dotan
?Antibody-Drug Conjugates: To Join or Not to Join?
Anthony W. Tolcher, MD
?Panel Question and Answer
Panel Discussion
?Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. (Abstract 2506)
Jeffrey R. Infante
?Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy. (Abstract 2507)
Suzanne Leijen
?Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
(Abstract 2508)
Elizabeth Catherine Smyth
?Promising Novel Targets and Agents
Ryan Bruce Corcoran, MD, PhD
?Panel Question and Answer
Panel Discussion
Session Title: Latest Advances in Systemic Therapy for Bone Sarcomas
Session Type: Education Session
Track: Sarcoma
Time: 9:45 AM - 11:00 AM
Location: S504
?Chemotherapy for Adults with Bone Sarcomas
Robert S. Benjamin, MD
?Chemotherapy for Children with Bone Sarcomas
Paul A. Meyers, MD
?Novel Aproaches to the Treatment of Chondrosarcoma and Nonosteosarcoma of Bone Jonathan C. Trent, MD, PhD - Chair
?Panel Question and Answer
Session Title: Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on the Right Track?
Session Type: Education Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 9:45 AM - 11:00 AM
Location: E450
?Current and Emerging Cytotoxic and Targeted Therapeutics: An Expanding Landscape Andrew H. Ko, MD
?The Emerging Role of Immunotherapeutic Approaches in Pancreas Cancer: The Future Is Now
Tanios S. Bekaii-Saab, MD - Chair
?Of Nab-, Nano-, and Other Emerging Therapies in Pancreas Cancer: Do They Provide Good Value?
Neal J. Meropol, MD
?Panel Question and Answer
Session Title: Moving Survivorship Care Forward: Lessons from Quality Measures
Session Type: Education Session
Track: Patient and Survivor Care
Time: 9:45 AM - 11:00 AM
Location: S100bc
?Survivorship Quality Measures
Charles L. Shapiro, MD
?Integration of Survivorship Care Plans into Electronic Health Records Deborah Mayer, RN, PhD
?Using Quality Measures to Guide Improvements in Survivorship Care Mary S. McCabe, RN, MA - Chair
?Panel Question and Answer
Session Title: Optimizing Treatment of HER2-Positive Breast Cancer
Session Type: Education Session
Track: Breast Cancer
Time: 9:45 AM - 11:00 AM
Location: E Hall D1
?Neoadjuvant and Adjuvant Therapy for HER2-Positive Disease
Stephen K. L. Chia, MD - Chair
?Targeted Therapies for Metastatic HER2-Positive Disease
Sunil Verma, MD, MSEd, FRCP(C)
?Management of Brain Metastases in HER2-Positive Breast Cancer Michelle E. Melisko, MD
?Panel Question and Answer
Session Title: Universal Screening for BRCA1/2 Mutations: Good Idea or Bad Idea? Session Type: Education Session
Track: Cancer Prevention, Genetics, and Epidemiology
Time: 9:45 AM - 11:00 AM
Location: S102
?Moderator
Allison W. Kurian, MD, MSc - Chair
?The Pros of Universal Genetic Testing
Elizabeth M. Swisher, MD
?The Cons of Universal Genetic Testing
Mark E. Robson, MD
?Panel Question and Answer
Session Title: Molecular Drivers and Genomic Biomarkers in Genitourinary Cancers
Session Type: Clinical Science Symposium
Track: Genitourinary Cancer
Time: 9:45 AM - 11:15 AM
Location: S406
?Co-chair
Petros Grivas, MD, PhD
?Co-chair
Gopa Iyer, MD
?Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3. (Abstract 4509)
James Hsieh
?Molecular Predictors of Response in Renal Cell Cancer
Walter Michael Stadler, MD
?Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT). (Abstract 4510)
Darren Richard Feldman
?Using Sequencing as a New Risk Stratifier for Germ Cell Tumors
Carsten Bokemeyer, MD
?Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer. (Abstract 4511)
Randy F. Sweis
?Genomics and Inflammation in Genitourinary Tumors
William Y. Kim, MD
?Panel Question and Answer
Session Title: Myeloma
Session Type: Oral Abstract Session
Track: Lymphoma and Plasma Cell Disorders
Time: 9:45 AM - 12:45 PM
Location: E354b
?Co-chair
Saad Zafar Usmani, MD
?Co-chair
Thomas G. Martin, III, MD
?ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide
(Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with
relapsed/refractory multiple myeloma (RRMM). (Abstract 8508)
Sagar Lonial
?Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.
(Abstract 8509)
Meletios A. Dimopoulos
?Using Big Data to Guide Therapeutic Decisions for Early-Relapsed Multiple Myeloma Jeffrey Lee Wolf, MD
?Panel Question and Answer
?Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). (Abstract 8510)
Todd M. Zimmerman
?Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM). (Abstract 8511)
Christian Straka
?Optimal Management of Newly Diagnosed Transplant-Eligible Multiple Myeloma Saad Zafar Usmani, MD
?Panel Question and Answer
Panel Discussion
?Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).
(Abstract LBA8512)
Sagar Lonial
? A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM). (Abstract 8513) Jesus G. Berdeja
?Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. (Abstract 8514)
Morie A. Gertz
?New Drug Classes in Plasma Cell Disorders
Suzanne Lentzsch, MD, PhD
?Panel Question and Answer
Panel Discussion
Session Title: Immunotherapy for Genitourinary Tumors: Are We Ready for Prime Time? Session Type: Education Session
Track: Genitourinary Cancer
Time: 11:30 AM - 12:45 PM
Location: S406
?Immunotherapeutic Approaches in Prostate Cancer, Combinations, and Clinical Integration Susan F. Slovin, MD, PhD, FACP - Chair
?Evolving Immunotherapy Strategies in Urothelial Carcinoma
Piyush K. Agarwal, MD
?Emerging Role for Novel Immunotherapy Agents in Renal Cell Carcinoma: From Bench to Bedside
David F. McDermott, MD
?Panel Question and Answer
Session Title: Managing Side Effects of Endocrine Therapy in Men and Women
Session Type: Education Session
Track: Patient and Survivor Care
Time: 11:30 AM - 12:45 PM
Location: S100bc
?Don't Break the Bones
Catherine H. Van Poznak, MD
?Sexual Healing in Men with Cancer
Leslie R. Schover, PhD
?Don't Lose That Loving Feeling: Sexual Health in Women with Cancer
Shari Beth Goldfarb, MD - Chair
?Panel Question and Answer
Session Title: The Many Faces of Neuroendocrine Cancers
Session Type: Education Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 11:30 AM - 12:45 PM
Location: E450
?Pathologist Perspective
David Klimstra, MD
?Lung Cancer
Rogerio Lilenbaum, MD
?Prostate Cancer
Himisha Beltran, MD
?Pancreatic Cancer
Emily K. Bergsland, MD - Chair
?Panel Question and Answer
Session Title: Well-Differentiated and Dedifferentiated Liposarcoma: New Challenges and New Directions
Session Type: Education Session
Track: Sarcoma
Time: 11:30 AM - 12:45 PM
Location: S504
?Dissecting the Molecular Biology of Liposarcoma for Therapeutic Interventions and Novel Surgical Approaches
Samuel Singer, MD - Chair
?Understanding the Biology of CDK4 Targeting: A Biomarker-Driven Approach to Patient Selection
Andrew Koff, PhD
?MDM2 Targeting in Liposarcoma: Where Are We Going and Will Toxicites Impede Drug Development in Liposarcoma?
Gary K. Schwartz, MD
?Panel Question and Answer